A $475,000 price tag for a new cancer drug: crazy or meh?
We need to wait and see how well it works before knowing if the $475,000 price tag on Novartis's new cancer drug is too high or too low.
Forget McGregor-Mayweather. The biotech world has been waiting for months to hear about Novartis’s pricing decision for Kymriah, its just-approved CAR-T therapy for cancer. That interest turned into anxiety days earlier when Gilead announced its purchase of Kite, given that Kite is expected to be the next company to market its own CAR-T treatment and Gilead — rightly or wrongly — is viewed as a company ready to push the envelope on price in service of its shareholders.
So in the past few days, we have learned that McGregor is not
